
Sign up to save your podcasts
Or
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZPF865. CME credit will be available until January 26, 2026.
Charting a New Course in Limited-Stage SCLC Amid an Immunotherapy Sea Change: Elevating Curative-Intent Treatment Approaches
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure information is available at the beginning of the video presentation.
4.3
99 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZPF865. CME credit will be available until January 26, 2026.
Charting a New Course in Limited-Stage SCLC Amid an Immunotherapy Sea Change: Elevating Curative-Intent Treatment Approaches
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure information is available at the beginning of the video presentation.
130 Listeners
5 Listeners
31 Listeners
3 Listeners
3 Listeners
10 Listeners
5 Listeners
28 Listeners
9 Listeners
3 Listeners
2 Listeners
5 Listeners
3 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
316 Listeners
42 Listeners
2 Listeners
110 Listeners
2 Listeners
480 Listeners
54 Listeners
43 Listeners
21 Listeners
321 Listeners
54 Listeners
9 Listeners
166 Listeners
36 Listeners